Welcome to our dedicated page for Gossamer Bio SEC filings (Ticker: GOSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gossamer Bio, Inc. (GOSS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), and its filings offer detailed insight into this strategy.
Through current reports on Form 8‑K, Gossamer Bio reports material events such as quarterly financial results, stockholder meeting outcomes, and significant transactions. Recent 8‑K filings have described results of operations and financial condition, approval of amendments to its 2019 Incentive Award Plan, and the option agreement and plan of merger that grant Gossamer Bio the right to acquire Respira Therapeutics and its pulmonary hypertension candidate RT234. These documents outline share issuances, potential milestone payments, and other key terms.
Investors can also use this page to locate references to the company’s incentive equity plans, employment inducement awards, and stockholder voting results, which appear in filings related to annual meetings and compensation arrangements. While Forms 10‑K and 10‑Q are not reproduced here, they are accessible through EDGAR and provide comprehensive information on research and development expenses, collaboration revenue, cash resources, and risk factors tied to seralutinib and the broader pipeline.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in clear language. Users can quickly understand the main points of lengthy reports, track how new equity issuances affect capital structure, and see how clinical and business milestones are reflected in Gossamer Bio’s regulatory record. Real-time updates ensure that new 8‑K, 10‑Q, 10‑K, and Form 4 insider transaction filings for GOSS are surfaced as they are posted to EDGAR, helping users follow the company’s evolving disclosure history.
Gossamer Bio, Inc. (GOSS) Chief Operating and Financial Officer Bryan Giraudo reported an award of 181,250 performance stock units on 10/01/2025. The award is a non‑cash grant that will vest in full upon the earlier of: approval of a new drug application for seralutinib or a change in control, provided vesting occurs on or before the fourth anniversary of the grant and the reporting person remains in continuous service. Following the reported grant, Mr. Giraudo beneficially owns 273,987 shares directly and 480,010 shares indirectly through a family trust, for combined reported beneficial ownership disclosed on the form.
Richard Aranda, Chief Medical Officer of Gossamer Bio, Inc. (GOSS), reported receiving a performance stock unit award of 162,500 common stock units on 10/01/2025. The award carries a $0 purchase price and will vest in full upon the earlier of (i) approval of a new drug application for seralutinib or (ii) a change in control, provided vesting occurs on or before the fourth anniversary of the grant date and subject to the reporting person’s continuous service. After the reported transaction, the filing shows 369,356 shares beneficially owned directly and 2,539 shares beneficially owned indirectly through a family trust. The filing was signed by an attorney-in-fact on 10/02/2025.
Hasnain Faheem, President & CEO and a director of Gossamer Bio, Inc. (GOSS), reported a non‑derivative acquisition dated 10/01/2025 of 437,500 performance stock units at a reported price of $0. After the award, the filing shows 557,793 shares beneficially owned directly and 5,408,073 shares beneficially owned indirectly through a family trust. The performance stock units will vest in full upon the earlier of the approval of a new drug application for seralutinib or a change in control, in either case on or before the fourth anniversary of the grant date, and are subject to the reporting person’s continuous service to the issuer. The Form 4 was signed on 10/02/2025 by an attorney‑in‑fact.
Caryn Peterson, Executive Vice President, Regulatory Affairs of Gossamer Bio, Inc. (GOSS), reported the acquisition of 125,000 performance stock units on 10/01/2025. The award is a performance stock unit grant that vests in full upon the earlier of (i) approval of a new drug application for seralutinib or (ii) a change in control, in either case on or before the fourth anniversary of the grant date, and is subject to the reporting person’s continuous service. After the transaction the reporting person beneficially owns 174,833 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Gossamer Bio, Inc. issued 2,500,000 shares of common stock to Prana on September 24, 2025 as consideration for a Company Merger Option. The Company agreed that, upon exercise of the Merger Option at closing, it would issue up to an additional 1,500,000 shares. The agreement also provides for cash and stock milestone payments following achievement of specified regulatory and sales milestones, including potential issuance of up to approximately 6,688,964 additional shares of common stock. The number of milestone shares to be issued will be calculated by dividing the applicable milestone obligation value by the average closing price on the Nasdaq Global Select Market for the thirty consecutive trading days ending two trading days before achievement of the milestone. The transactions are being made in reliance on Section 4(a)(2) of the Securities Act of 1933.
Sandra Milligan, a director of Gossamer Bio, purchased 26,050 shares of the company's common stock on 08/19/2025 at $1.92 per share, increasing her beneficial ownership to 58,050 shares. The transaction is reported on a Form 4 covering non-derivative securities. The filing indicates the purchase was reported individually by the reporting person.
Gossamer Bio, Inc. (GOSS) – Form 4 insider transaction
Director Thomas O. Daniel received an equity award on 06/25/2025 consisting of 115,000 non-qualified stock options with an exercise price of $1.36 and an expiration date of 06/24/2035. The grant was made under the company’s Non-Employee Director Compensation Program.
All options vest in full on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting of shareholders, contingent on continued board service. The filing lists the transaction code “A” (acquisition) and shows 115,000 derivative securities beneficially owned directly after the transaction. No common shares were bought or sold.
- Standard director compensation; no immediate cash outlay by the insider.
- Filing signed on 06/26/2025 by Attorney-in-Fact Jeff Boerneke.
- No other changes in ownership disclosed.